Cyp3a41b Inhibitors
Cyp3a41b inhibitors are a specialized class of chemical compounds that specifically target and inhibit the activity of the Cyp3a41b enzyme, which is a member of the cytochrome P450 superfamily. The Cyp3a41b enzyme plays a significant role in the oxidative metabolism of a diverse array of substrates, including endogenous molecules such as hormones, steroids, and fatty acids, as well as exogenous compounds like pharmaceuticals and environmental toxins. As part of the cytochrome P450 family, Cyp3a41b is involved in the monooxygenation process, where it catalyzes the insertion of an oxygen atom into the substrate molecule. This biochemical transformation typically enhances the solubility of these lipophilic substrates, facilitating their further metabolism, conjugation, or excretion from the body. The enzyme's activity is particularly crucial in the liver, where it contributes to the detoxification of potentially harmful substances and the regulation of metabolic pathways essential for maintaining homeostasis.
Inhibitors of Cyp3a41b are generally small molecules designed to bind specifically to the enzyme's active site, thereby preventing it from interacting with and oxidizing its natural substrates. These inhibitors may function by occupying the substrate-binding pocket, effectively blocking the access of substrates to the catalytic site, or by inducing conformational changes that diminish the enzyme's catalytic efficiency. The development of Cyp3a41b inhibitors requires detailed structural analysis of the enzyme, focusing on the critical regions involved in substrate recognition and catalytic activity. By inhibiting Cyp3a41b, researchers can gain insights into the specific role of this enzyme in various metabolic processes and assess how its inhibition affects the broader network of cytochrome P450-mediated reactions. The study of Cyp3a41b inhibitors is essential for understanding the enzyme's substrate specificity, its interactions with other metabolic enzymes, and its overall contribution to the metabolism and detoxification processes within the body. This research enhances our knowledge of the functional diversity within the cytochrome P450 superfamily and underscores the importance of these enzymes in regulating the complex metabolic pathways that sustain biological systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Aminoglutethimide | 125-84-8 | sc-207280 sc-207280A sc-207280B sc-207280C | 1 g 5 g 25 g 100 g | $41.00 $143.00 $530.00 $2020.00 | 2 | |
Aromatase inhibitor acting as a direct inhibitor of Cyp3a41b. By suppressing aromatase activity, it directly inhibits the target protein within the endoplasmic reticulum and membrane, impacting heme and iron ion binding activities. | ||||||
Anastrozole | 120511-73-1 | sc-217647 | 10 mg | $90.00 | 1 | |
Aromatase inhibitor known to inhibit Cyp3a41b. By directly suppressing aromatase activity, it hinders both heme and iron ion binding activities, contributing to the direct inhibition of the target protein within the endoplasmic reticulum and membrane. | ||||||
Letrozole | 112809-51-5 | sc-204791 sc-204791A | 25 mg 50 mg | $85.00 $144.00 | 5 | |
Aromatase inhibitor with inhibitory effects on Cyp3a41b. It directly suppresses aromatase activity, impacting both heme and iron ion binding activities, contributing to the direct inhibition of the target protein within the endoplasmic reticulum and membrane. | ||||||
Exemestane | 107868-30-4 | sc-203045 sc-203045A | 25 mg 100 mg | $131.00 $403.00 | ||
Irreversible aromatase inhibitor acting as a direct inhibitor of Cyp3a41b. By directly inhibiting aromatase activity, it disrupts both heme and iron ion binding activities, contributing to the direct inhibition of the target protein within the endoplasmic reticulum and membrane. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $62.00 $260.00 | 21 | |
Broad-spectrum antifungal agent acting as an indirect inhibitor of Cyp3a41b. By hindering the heme and iron ion binding activities, it indirectly disrupts aromatase activity, contributing to the inhibition of the target protein within the endoplasmic reticulum and membrane. | ||||||
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $53.00 $84.00 | 14 | |
Azole antifungal compound acting as an indirect inhibitor of Cyp3a41b. It interferes with heme and iron ion binding activities, indirectly impacting aromatase activity and contributing to the inhibition of the target protein within the endoplasmic reticulum and membrane. | ||||||
Anagrelide hydrochloride | 58579-51-4 | sc-203513 sc-203513A | 10 mg 50 mg | $103.00 $587.00 | 1 | |
Platelet-reducing agent known to indirectly inhibit Cyp3a41b. By impacting heme and iron ion binding activities, it indirectly disrupts aromatase activity, contributing to the inhibition of the target protein within the endoplasmic reticulum and membrane. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $66.00 | 4 | |
Proton pump inhibitor acting as an indirect inhibitor of Cyp3a41b. By hindering the heme and iron ion binding activities, it indirectly disrupts aromatase activity, contributing to the inhibition of the target protein within the endoplasmic reticulum and membrane. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $256.00 | 18 | |
Selective estrogen receptor modulator with inhibitory effects on Cyp3a41b. By impacting heme and iron ion binding activities, it indirectly disrupts aromatase activity, contributing to the inhibition of the target protein within the endoplasmic reticulum and membrane. | ||||||
Clotrimazole | 23593-75-1 | sc-3583 sc-3583A | 100 mg 1 g | $41.00 $56.00 | 6 | |
Imidazole antifungal compound acting as an indirect inhibitor of Cyp3a41b. It interferes with heme and iron ion binding activities, indirectly impacting aromatase activity and contributing to the inhibition of the target protein within the endoplasmic reticulum and membrane. | ||||||